- NCIt
- C7543
Loading cancer entity…
Loading cancer entity…
Clinical trials
59 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (5)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02567409 | Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer | completed | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT03513952 | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Jul 26, 2024 | clinicaltrials |
| NCT01326871 | A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer | completed | Phase 1 / Phase 2 | 68 | Altor BioScienceINDUSTRY | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03617913 | Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer | completed | Phase 2 | 2 | Mayo ClinicOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT03520231 | Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases | completed | Phase 2 | 6 | University Health Network, TorontoOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT00749892 | Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer | completed | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT02178241 | Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 2 | Dec 16, 2019 | clinicaltrials |
| NCT02665039 | A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function(VINGEM) | completed | Phase 2 | 62 | Dr Anders UllénOTHER | 2 | Oct 8, 2019 | clinicaltrials |
| NCT01282463 | Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma | completed | Phase 2 | 148 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 9, 2019 | clinicaltrials |
| NCT01191892 | Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer | completed | Phase 2 | 82 | Cardiff UniversityOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT01328574 | TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Jan 13, 2017 | clinicaltrials |
| NCT00072150 | Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00009867 | Arsenic Trioxide in Treating Patients With Urothelial Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT01426126 | Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum | completed | Phase 2 | 37 | Asan Medical CenterOTHER | 1 | Dec 7, 2011 | clinicaltrials |
| NCT00661609 | A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer | completed | Phase 2 | 54 | AstraZenecaINDUSTRY | 5 | Jan 12, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Mar 3, 2025source: clinicaltrials